ClearPoint faces pressure from weak 2026 guidance and regulatory uncertainty, but partner therapy launches could drive ...

SOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of ...

ClearPoint Neuro reported total operating expenses of $11.3 million in the quarter. The company ended the period with $12.4 million in cash and cash equivalents. “Our 2025 fiscal year is off to a ...

Deep Sail Capital, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The fund returned 5.8% net of fees in the third quarter, ...

ClearPoint Neuro Inc. (NASDAQ:CLPT) shares are trading higher Wednesday after the company announced results from a Phase I-II clinical study evaluating its ClearPoint Prism Neuro Laser Therapy System.

(RTTNews) - Shares of ClearPoint Neuro Inc. (CLPT) are up nearly 40% at $17 in premarket trading on Wednesday. This global device, cell, and gene therapy-enabling company operates in two segments: (i) ...

One stock that might be an intriguing choice for investors right now is ClearPoint Neuro, Inc. CLPT. This is because this security in the Medical – Instruments space is seeing solid earnings estimate ...